分析急性心肌梗死合并室性心律失常采用酒石酸美托洛尔联合盐酸胺碘酮治疗的效果

Analysis of the Effect of Acute Myocardial Infarction with Ventricular Arrhythmia Treated with Metoprolol Tartrate and Amiodarone Hydrochloride

目的研究对急性心肌梗死合并室性心律失常的患者实施酒石酸美托洛尔与盐酸胺碘酮联合用药的临床治疗效果。方法方便选取2016年3月-2017年3月在该院进行治疗急性心肌梗死合并室性心律失常的患者,共86例,根据入院时间分为Z组和C组,C组患者予以酒石酸美托洛尔进行常规治疗,Z组予以酒石酸美托洛尔与盐酸胺碘酮联合用药进行治疗,对比两组患者的B型利钠肽(BNP)和血清磷酸肌酸激酶同工酶(CK-MB)的改善情况、两组患者的临床治疗效果以及两组患者出现不良反应的情况。结果 Z组患者实施联合用药后BNP的改善情况均好于C组患者单一用药后的改善情况(t=98.293,P=0.000);Z组患者实施联合用药后CK-MB的改善情况均好于C组患者单一用药后的改善情况(t=67.025,P=0.000);Z组患者的临床治疗总有效率(93.02%)明显高于C组临床治疗总有效率(81.39%)(χ~2=13.961,P=0.000)。结论酒石酸美托洛尔联合盐酸胺碘酮治疗急性心肌梗死合并室性心律失常的效果比单一用药效果更好,在提高患者临床治疗效果的同时改善患者的临床指标,具有临床推广的意义。

Objective To study the clinical effect of metoprolol tartrate combined with amiodarone hydrochloride in patients with acute myocardial infarction and ventricular arrhythmia. Methods From March 2016 to March 2017, 86 patients with acute myocardial infarction complicated with ventricular arrhythmia were convenient selected and divided into group Z and group C according to admission time. Group C received metoprolol tartrate for routine treatment and group Z received metoprolol tartrate combined with amiodarone hydrochloride for treatment. The improvement of B-type natriuretic peptide(BNP) and creatine kinase isoenzyme(CK-MB) were compared between the two groups. The clinical efficacy of the two groups and the adverse reactions of the two groups were compared. Results The improvement of BNP in group Z was better than that in group C(t=98.293, P=0.000), and the improvement of CK-MB in group Z was better than that in group C(t=67.025, P=0.000). The rate(93.02%) was significantly higher than the total effective rate(81.39%) in group C(χ~2=13.961,P =0.000). Conclusion Metoprolol tartrate combined with amiodarone hydrochloride is more effective than single drug in treating acute myocardial infarction complicated with ventricular arrhythmia. It can improve the clinical therapeutic effect of patients and improve the clinical indicators, and has the significance of clinical promotion.